喉癌手术患者血清肝细胞生长因子和血清中细胞角蛋白18水平对患者预后的影响

Effect of serum HGF and CK18 in patients with laryngeal cancer on postoperative prognosis

目的:探讨喉癌患者血清中细胞角蛋白18(CK18)和肝细胞生长因子(HGF)与患者肿瘤分期及预后的相关性。方法:选取200例喉癌患者,均给予手术治疗,采集血样检测CK18及HGF水平,定期随访采集患者术后相关资料。结果:中低分化程度、肿瘤分级、临床分期较高的患者血清CK18和HGF浓度显著高于高分化程度、肿瘤分级较低、临床分期较低的患者,差异有统计学意义(P<0.05)。高CK18组喉癌患者5年期生存率(69.9%)显著低于低CK18组患者(92.3%),2组比较差异有统计学意义(P<0.05);高HGF组喉癌患者5年期生存率(71.1%)显著低于低HGF组患者(94.2%),差异有统计学意义(P<0.05)。单因素分析结果显示肿瘤类型、分化程度、T分级、N分级、临床分期影响喉癌患者生存率;Cox回归模型分析表明高CK18与高HGF水平是预后的危险因素[CK18HR:2.594(1.558~4.318);P<0.01,HGF HR:2.671(1.605~4.446);P<0.01]。结论:血清CK18和HGF水平可作为喉癌预后和疾病监测的生物标志物。

Objective:To investigate the correlation between the levels of serum cytokeratin 18(CK18)and hepatocyte growth factor(HGF)and tumor stage and prognosis in patients with laryngeal carcinoma.Method:Patients with laryngeal cancer who were admitted to our hospital from January 2012 to December 2013 were enrolled.Blood samples were collected for CK18 and HGF detection,and postoperative prognosis data were collected at regular follow-up.Result:The serum CK18 and HGF concentration of patients with poorly differentiated tumor,high tumor grade and clinical stage were significantly higher than those with well-differentiated tumor,low tumor grade and low clinical stage(P<0.05).The 5-year survival rate(69.9%)of patients with laryngeal cancer in the high CK18 group was significantly lower than that in the low CK18 group(92.3%)(P<0.05),and the 5-year survival rate(71.1%)of patients with laryngeal cancer in the high HGF group was significantly lower than that in the low HGF group(94.2%)(P<0.05).The results of univariate analysis showed that tumor type,differentiation,T grade,N grade and clinical stage affected the survival rate of patients with laryngeal cancer.Cox regression model analysis showed high CK18 and high HGF levels were risk factors for poor prognosis[CK18 HR:2.594(1.558-4.318);P<0.001,HGF HR:2.671(1.605-4.446);P<0.001].Conclusion:The results suggested that serum CK18 and HGF levels can be used as prognostic and disease monitoring biomarkers for laryngeal cancer.